Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 1, 2025Neuro-OncologyOpen Access

DDEL-26. Modulation of the Blood-Tumor Barrier Using Small-Molecule Inhibitors: Enhancing Chemotherapeutic Penetration in Glioblastoma Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

PVPhilippa Vaughn-Beaucaire

Discussion

Loading...

Member takes

Overview

Experimental modulation of the blood-brain barrier boosts cisplatin efficacy in glioblastoma, suggesting dasatinib as a potential alternative.

Key Points

  • This research aims to investigate mechanisms for enhancing drug delivery in glioblastoma through blood-tumor barrier modulation.
  • Utilized bulk RNA sequencing and spatial transcriptomics to analyze BTB characteristics.
  • Examined the effects of the small-molecule inhibitor BIA on CDH5 expression and endothelial barrier integrity.
  • Conducted in vitro and in vivo experiments in murine GBM xenograft models to assess drug delivery and efficacy of cisplatin and dasatinib.
  • BIA treatment decreased CDH5 and improved cisplatin accumulation in GBM tumors, extending survival in mice.
  • Dasatinib similarly disrupted blood-tumor barrier integrity, enhancing drug penetration.
  • Overall, targeting the BTB significantly improved therapeutic outcomes compared to standard approaches.

Cite This Study

Philippa Vaughn-Beaucaire (2025) studied this question.

synapsesocial.com/papers/6925436cc0ce034ddc3585c5https://doi.org/10.1093/neuonc/noaf201.0631
View Full Paper
Ask AI
Bookmark
Share